EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pre-Clinical Models for CAR T-Cell Therapy for Glioma

Gust Vandecandelaere iD, Rishab Ramapriyan, Matthew Gaffey, Leland Geoffrey Richardson, Samuel Jeffrey Steuart iD, Masih Tazhibi, Adrian Kalaw iD, Eric P Grewal iD, Jing Sun, William T Curry, Bryan D Choi iD

Cells · 2024

DOI: 10.3390/cells13171480 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Gust Vandecandelaere und 10 weiteren Autor:innen. Beteiligte Einrichtung: Brain Tumor Immunotherapy Lab, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Glioma, Immunotherapy, Adoptive, Brain Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Belgian American Educational Foundation, The Jenny Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy represents a transformative shift in cancer treatment. Among myriad immune-based approaches, chimeric antigen receptor (CAR) T-cell therapy has shown promising results in treating hematological malignancies. Despite aggressive treatment options, the prognosis for patients with malignant brain tumors remains poor. Research leveraging CAR T-cell therapy for brain tumors has surged in recent years. Pre-clinical models are crucial in evaluating the safety and efficacy of these therapies before they advance to clinical trials. However, current models recapitulate the human tumor environment to varying degrees. Novel in vitro and in vivo techniques offer the opportunity to validate CAR T-cell therapies but also have limitations. By evaluating the strengths and weaknesses of various pre-clinical glioma models, this review aims to provide a roadmap for the development and pre-clinical testing of CAR T-cell therapies for brain tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaImmunotherapy, AdoptiveBrain NeoplasmsReceptors, Chimeric AntigenHumansAnimalsT-LymphocytesDisease Models, AnimalReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

CAR T-cell therapygliomaimmunotherapypre-clinical modelssolid tumors

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Brain Tumor Immunotherapy Lab, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Faculty of Medicine, KU Leuven, 3000 Leuven, Belgium.

ORCID-Profile: Gust Vandecandelaere, Samuel Jeffrey Steuart, Adrian Kalaw, Eric P Grewal, Bryan D Choi

Förderung

  • NIGMS NIH HHS
  • Belgian American Educational Foundation
  • The Jenny Fund
  • A Shot for Life
  • Swim Across America
  • the Marcus Foundation
  • the Brian D. Silber Memorial Fund
  • HHS/National Institutes of Health (NIH)

Zitieren

APA

Vandecandelaere, G., Ramapriyan, R., Gaffey, M., Richardson, L. G., Steuart, S. J., Tazhibi, M., Kalaw, A., Grewal, E. P., Sun, J., Curry, W. T., & Choi, B. D. (2024). Pre-Clinical Models for CAR T-Cell Therapy for Glioma. Cells. https://doi.org/10.3390/cells13171480

Vancouver

Vandecandelaere G, Ramapriyan R, Gaffey M, Richardson LG, Steuart SJ, Tazhibi M, et al. Pre-Clinical Models for CAR T-Cell Therapy for Glioma. Cells. 2024. doi:10.3390/cells13171480

BibTeX
@article{Vandecandelaere2024,
  author = {Vandecandelaere, Gust and Ramapriyan, Rishab and Gaffey, Matthew and Richardson, Leland Geoffrey and Steuart, Samuel Jeffrey and Tazhibi, Masih and Kalaw, Adrian and Grewal, Eric P and Sun, Jing and Curry, William T and Choi, Bryan D},
  title = {Pre-Clinical Models for CAR T-Cell Therapy for Glioma},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13171480}
}
Kostenlos starten →